In this interview for ASMS 2024, Liusheng Huang of the University of California San Francisco discusses his upcoming presentation about performing microvolume analysis on antimalarial drugs.
During ASMS 2024, which will take place June 2–6, 2024 in Anaheim, California, many scientists are set to present research on the latest advances in mass spectrometry. Recently, LCGC International sat down with Liusheng Huang of the University of California San Francisco to discuss his presentation, “Microvolume Analysis of Antimalarial Drugs for Pediatric Pharmacokinetic Studies."
Huang is the codirector of the Drug Research Unit (DRU) in the Department of Clinical Pharmacy at the University of California San Francisco. In his own words, "I bring nearly 20 years experience in analytical development and focus on development of novel methods for some of the most critical but understudied drugs in the world, such as drugs for malaria" (1). He received a BS in Medicinal Chemistry from the School of Pharmaceutical Sciences at Beijing Medical University in Beijing, China in 1992. Further, he earned his PhD for Pharmaceutical Sciences from Wayne State University in 2003. His research interests revolve around optimizing novel methods for quantitating drugs as close to the site of pharmacological action as possible, with an overarching goal of treating patients with the best drug regimens.
In this interview, Huang answers the following questions:
(1) Liusheng Huang, PhD. The Regents of the University of California 2024. https://pharmacy.ucsf.edu/liusheng-huang (accessed 2024-5-21)
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.
Exploring The Chemical Subspace of RPLC: A Data-driven Approach
November 11th 2024Saer Samanipour from the Van ‘t Hoff Institute for Molecular Sciences (HIMS) at the University of Amsterdam spoke to LCGC International about the benefits of a data-driven reversed-phase liquid chromatography (RPLC) approach his team developed.